Infinity BiologiX and Cytox collaborate to provide new genetic test to predict the risk of cognitive decline due to Alzheimer’s Disease

Powered by Cytox’s genoSCORE, the new test enables physicians to support patients with lifestyle changes, and guide possible use of drug therapy, to delay the onset of disease symptoms

PISCATAWAY, N.J. & OXFORD, England & MANCHESTER, England--(BUSINESS WIRE)--Today, Infinity BiologiX, LLC (IBX) and Cytox Ltd, announce a collaboration to provide a new, non-invasive, genetic test that can predict the risk of cognitive decline due to Alzheimer’s through a simple saliva or blood sample. The product is anticipated to be available to physicians in the coming months.

Physicians can use the genoSCORE test to assess patients before symptoms arise, and prior to invasive cerebrospinal fluid (CSF) testing or expensive scanning techniques. Furthermore, the test’s simplicity of use enables elderly and vulnerable patients not able to attend healthcare settings, to provide a sample from home.

Dr. Richard Pither, CEO of Cytox, commented: “Alzheimer’s disease affects over 46 million people in the world¹. We see this new test as a powerful tool to enable physicians to make immediate decisions about their patients’ risk of cognitive decline due to Alzheimer’s disease, and guide them towards effective lifestyle and therapeutic interventions that can have a significant impact on delaying the onset of disease symptoms and cognitive decline². We are delighted to be working with IBX, a leading provider of laboratory tests that can bring this new product to US physicians and their patients.”

Robin Grimwood, IBX CEO, explained, “We see this agreement for the sale and distribution of the genoSCORE-powered test as a critical collaboration in line with our mission to understand the genetic causes of common, complex diseases, such as Alzheimer’s, and to discover diagnoses, treatments and, support the development of new, effective therapeutic interventions for these diseases.”